Compare SPRO & BLNK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SPRO | BLNK |
|---|---|---|
| Founded | 2013 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Specialties |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.6M | 85.6M |
| IPO Year | 2017 | 2008 |
| Metric | SPRO | BLNK |
|---|---|---|
| Price | $1.20 | $0.56 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.33 |
| AVG Volume (30 Days) | ★ 1.5M | 1.3M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 111.81 | 61.22 |
| EPS | N/A | ★ N/A |
| Revenue | $66,802,000.00 | ★ $126,197,000.00 |
| Revenue This Year | N/A | $5.71 |
| Revenue Next Year | $300.00 | $19.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 39.24 | N/A |
| 52 Week Low | $1.08 | $0.45 |
| 52 Week High | $3.08 | $2.65 |
| Indicator | SPRO | BLNK |
|---|---|---|
| Relative Strength Index (RSI) | 31.16 | 46.26 |
| Support Level | $1.10 | $0.54 |
| Resistance Level | $1.28 | $0.72 |
| Average True Range (ATR) | 0.06 | 0.04 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 40.00 | 55.03 |
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. It is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.